Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
तुलना करने के लिए मीट्रिक्स | PLX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPLXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 30.6x | 116.7x | −0.6x | |
PEG अनुपात | 0.20 | −0.56 | 0.00 | |
क़ीमत/बुक | 3.1x | 4.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.7x | 6.6x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 139.1% | 42.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.6% | 5.8% | अनलॉक करें |